MYOS - MYOS RENS Technology Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.38
+0.01 (+0.73%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.37
Open1.37
Bid1.32 x 4000
Ask1.43 x 900
Day's Range1.34 - 1.40
52 Week Range1.03 - 2.50
Volume80,759
Avg. Volume216,123
Market Cap10.314M
Beta1.75
PE Ratio (TTM)N/A
EPS (TTM)-0.68
Earnings DateMar 29, 2018 - Apr 2, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ACCESSWIRE4 days ago

    Today's Research Reports on Trending Tickers: MYOS RENS Technology and Canopy Growth

    The Dow Jones Industrial Average declined 0.88 percent to close at 24,700.45, while the S&P 500 Index dropped 0.71 percent to close at 2,774.02. The Nasdaq Composite Index shed 0.55 percent to close at 7,716.61. It’s unclear what it might do next, but it is clearly another step closer to a full-blown trade war,” according to David Carter, chief investment officer at Lenox Wealth Advisors.

  • PR Newswirelast month

    MYOS RENS Technology Launches Advanced Veterinary Supplement Product For Dogs, Powered By Fortetropin®

    CEDAR KNOLLS, N.J., June 6, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, today announced the launch of 'MYOS Canine Muscle Formula'.  This is the first product in the Company's new line of advanced veterinary health supplements to support muscle health in dogs, featuring Fortetropin® as the active ingredient. Joseph Mannello, Chief Executive Officer of the Company, stated, "We are excited to be launching our first veterinary health supplement, which helps support muscle health in dogs.

  • GlobeNewswire2 months ago

    Factors of Influence in 2018, Key Indicators and Opportunity within Insulet, Everi, Ciner Resources LP, Aluminum Corporation of China, Okta, and MYOS RENS Technology — New Research Emphasizes Economic Growth

    NEW YORK, May 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Insulet ...

  • Should You Buy MYOS RENS Technology Inc (NASDAQ:MYOS) Now?
    Simply Wall St.2 months ago

    Should You Buy MYOS RENS Technology Inc (NASDAQ:MYOS) Now?

    MYOS RENS Technology Inc (NASDAQ:MYOS), a personal products company based in United States, led the NasdaqCM gainers with a relatively large price hike in the past couple of weeks. Less-covered,Read More...

  • Zacks Small Cap Research2 months ago

    MYOS: Several Development-Related Milestones Upcoming

    MYOS RENS Technology (MYOS) reported Q1 ’18 financial results and provided a business update. While revenue remains muted, that was not unexpected as much of MYOS’ activities continue to be focused on further expanding the evidence surrounding Fortetropin and its beneficial effects in improving muscle health. This evidence-based approach has the potential to pay dividends in the form of more efficient (and successful) commercialization.

  • PR Newswire2 months ago

    MYOS RENS Technology Reports First Quarter Financial Results

    Provides Update on Clinical Studies Programs Conference Call to be Held Tomorrow at 11am ET CEDAR KNOLLS, N.J. , May 9, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or the "Company") ...

  • PR Newswire2 months ago

    /C O R R E C T I O N -- MYOS RENS Technology Inc./

    In the news release, MYOS RENS Technology Announces the Date for the Release of First Quarter 2018 Results, Conference Call and Webcast, issued 03-May-2018 by MYOS RENS Technology Inc. over PR Newswire, ...

  • ACCESSWIRE3 months ago

    Free Research Report as Lipocine Announced FY17 Financial Results

    Stock Monitor: MYOS RENS Technology Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 20, 2018 / Active-Investors.com has just released a free earnings report on Lipocine Inc. (NASDAQ: LPCN ). If ...

  • Zacks Small Cap Research3 months ago

    MYOS: A New Product For Sports Nutrition

    MYOS RENS Technology, Inc. (MYOS) announced on April 10, 2018 that it has expanded its product line with the addition of Yolked™. Yolked™ received the Certified for Sport® certification from NSF International. NSF International is an independent organization that provides third-party certification of manufacturing systems and processes as well as for food, water and other products.

  • Was MYOS RENS Technology Inc’s (NASDAQ:MYOS) Earnings Growth Better Than The Industry’s?
    Simply Wall St.3 months ago

    Was MYOS RENS Technology Inc’s (NASDAQ:MYOS) Earnings Growth Better Than The Industry’s?

    For investors with a long-term horizon, examining earnings trend over time and against industry peers is more insightful than looking at an earnings announcement in one point in time. InvestorsRead More...

  • PR Newswire3 months ago

    MYOS RENS Technology Introduces New Sports Nutrition Product Line, Yolked™, and Earns Prestigious "Certified For Sport®" Certification From NSF International

    NSF "Certified for Sport®" Certification Further Demonstrates MYOS' Commitment To Providing Safe, Quality Products CEDAR KNOLLS, N.J. , April 10, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ...

  • Zacks Small Cap Research3 months ago

    MYOS: Initiation Report

    Headquartered in Cedar Knolls, NJ, MYOS RENS Technology Inc. (MYOS) is an emerging advanced nutrition and biotherapeutics company. MYOS received patent (U.S. Patent No. 8,815,320 B2) entitled “Process for Producing a Composition Containing Active Follistatin” to cover the proprietary manufacturing of Fortetropin in August 2014 from the USPTO. Fortetropin is a bioactive proteo-lipid complex.

  • PR Newswire3 months ago

    MYOS RENS Technology to Present at the MicroCap Conference April 10 in New York City at the Essex House

    CEDAR KNOLLS, N.J., April 3, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS), a bionutrition company and owner of Fortetropin®, the natural product that helps build lean muscle in conjunction with resistance training, announced that the Company's Chief Executive Officer, Joseph Mannello, will present at the MicroCap Conference on Tuesday, April 10th at 12:30 p.m. Eastern Time at the Essex House in New York City. Mr. Mannello will also be available to participate in one-on-one meetings with investors who are registered to attend the conference. "We are excited about the opportunity to meet with investors to discuss our recent business developments," said Mr. Mannello.

  • PR Newswire4 months ago

    MYOS RENS Technology CEO Joseph Mannello Provides Comments On Operational And Financial Results For Fiscal Year 2017

    CEDAR KNOLLS, N.J., March 28, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS), a bionutrition company and owner of Fortetropin®, a proprietary  ingredient that helps build lean muscle in conjunction with resistance training, presents comments from Chief Executive Officer, Joseph Mannello, on the operational and financial results for the year ended December 31, 2017. "I want to start by saying a few words about our financial results for 2017.

  • ACCESSWIRE4 months ago

    MYOS RENS Technology Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 28, 2018 / MYOS RENS Technology Inc. (NASDAQ: MYOS ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 28, 2018 at 11:00 AM Eastern ...

  • PR Newswire4 months ago

    MYOS RENS Technology Reports Fourth Quarter And Fiscal 2017 Financial Results

    Revenue Increased 61% Over Prior Year; Gross Profit Margin of 41% Conference Call to be Held Tomorrow at 11am ET CEDAR KNOLLS, N.J. , March 27, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" ...

  • PR Newswire4 months ago

    MYOS RENS Technology, Inc. Announces Research Agreement with Rutgers University Focused on Discovery of Compounds and Products for Improving Muscle Health and Performance

    CEDAR KNOLLS, N.J., March 27, 2018 /PRNewswire/ -- MYOS RENS Technology, Inc. ("MYOS" or the "Company") (NASDAQ: MYOS), a bionutrition and  biotherapeutics company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has entered into a research agreement with Rutgers University, The State University of New Jersey, to engage Rutgers researchers in a program focused on discovering compounds and products for promoting the growth and development of muscle tissue. The discovery program will be led by Joseph W. Freeman, Ph.D., Associate Professor, Department of Biomedical Engineering at Rutgers' School of Engineering, who oversees the University's Musculoskeletal Tissue Regeneration Laboratory ("MoTR").

  • PR Newswire4 months ago

    MYOS RENS Technology Announces the Date for the Release of Fourth Quarter and Year Ended December 31, 2017 Results, Conference Call and Webcast

    Conference Call & Webcast: Wednesday, March 28, 2018 at 11:00 am ET CEDAR KNOLLS, N.J. , March 20, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: ...

  • PR Newswire5 months ago

    MYOS RENS Technology to Showcase Fortetropin® and the Qurr® Line of Muscle Health Products at the 2018 Arnold Sports Festival in Columbus, OH from March 2-4, 2018

    Attendees of the Arnold Fitness EXPO can Sample Qurr® Powders, Puddings and Shakes, and Purchase Products with a Special Expo Discount at Booth #513. CEDAR KNOLLS, N.J., Feb. 15, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS), a bionutrition company and owner of Fortetropin®, the fertilized egg yolk-based product that helps build lean muscle in conjunction with resistance training, announced today that it will showcase Fortetropin® at the Arnold Fitness EXPO to be held during the Arnold Sports Festival March 2-4, 2018, at the Greater Columbus Convention Center in Columbus, Ohio.

  • PR Newswire6 months ago

    MYOS RENS Technology Launches 30-Day Qurr® Fortetropin® Challenge

    CEDAR KNOLLS, N.J., Jan. 16, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS), a bionutrition company and owner of Fortetropin®, the natural food product that helps build lean muscle in conjunction with resistance training, today launched the Qurr® Fortetropin® Challenge (the "Challenge"), a new initiative that combines Fortetropin®-based Qurr® products with a workout and support plan designed by an award-winning and nationally certified personal trainer, Scott Keppel.

  • PR Newswire6 months ago

    MYOS RENS Technology CEO Issues Shareholder Letter

    Throughout 2017, we made significant strides in building a sustainable foundation that will allow us to fully leverage the market opportunities of Fortetropin®, our proprietary all-natural food ingredient that has been clinically shown to increase lean muscle size and mass when taken in conjunction with resistance training. Because MYOS is a science-based company, we are committed to making investments in research that explore the therapeutic potential of Fortetropin® across many broad areas of muscle health. As such, we have engaged with two prestigious universities known for excellence in research, to confirm long known anecdotal evidence of the efficacy of Fortetropin® in muscle building.

  • PR Newswire7 months ago

    MYOS RENS Technology Enters Into Research Agreement With University Of California, Berkeley To Study Effects Of Fortetropin® On Skeletal Muscle Protein Synthetic Rate In Older Men And Women

    Clinical Study will be Completed and its Results Announced in the Second Half of 2018 CEDAR KNOLLS, N.J. , Dec. 6, 2017 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") ...

  • PR Newswire8 months ago

    MYOS RENS Technology Reports Third Quarter 2017 Financial Results

    Revenue Increased 312% over prior year; Gross Profit Margin of 59% New Marketing programs with NFL Alumni, IMG College Expected to Strengthen Future Sales CEDAR KNOLLS, N.J. , Nov. 14, 2017 /PRNewswire/ ...